* pregnant or breast feeding * suspected uncontrolled active bacterial, fungal, viral, or other infection other than covid-19 * treatment with a strong cytochrome p450 3a4 inhibitor or inducer within 7 days prior to day 1 * received anti-rejection or immunomodulatory drugs within 14 days prior to day 1 * concurrent participation in another clinical trial involving therapeutic interventions (observation studies are acceptable) * any condition that confounds the ability to interpret data from the study * any significant medical condition, laboratory abnormality, or psychiatric illness that would interfere with or prevent the subject from participating in the study

* pregnant or breast feeding * suspected uncontrolled active bacterial, fungal, viral, or other infection other than covid-19 * treatment with a strong cytochrome p450 3a4 inhibitor or inducer within 7 days prior to day 1 * received anti-rejection or immunomodulatory drugs within 14 days prior to day 1 * concurrent participation in another clinical trial involving therapeutic interventions (observation studies are acceptable) * any condition that confounds the ability to interpret data from the study * any significant medical condition, laboratory abnormality, or psychiatric illness that would interfere with or prevent the subject from participating in the study

- pregnant or breast feeding - suspected uncontrolled active bacterial, fungal, viral, or other infection other than covid-19 - treatment with a strong cytochrome p450 3a4 inhibitor or inducer within 7 days prior to day 1 - received anti-rejection or immunomodulatory drugs within 14 days prior to day 1 - concurrent participation in another clinical trial involving therapeutic interventions (observation studies are acceptable) - any condition that confounds the ability to interpret data from the study - any significant medical condition, laboratory abnormality, or psychiatric illness that would interfere with or prevent the subject from participating in the study

- pregnant or breast feeding - suspected uncontrolled active bacterial, fungal, viral, or other infection other than covid-19 - treatment with a strong cytochrome p450 3a4 inhibitor or inducer within 7 days prior to day 1 - received anti-rejection or immunomodulatory drugs within 14 days prior to day 1 - concurrent participation in another clinical trial involving therapeutic interventions (observation studies are acceptable) - any condition that confounds the ability to interpret data from the study - any significant medical condition, laboratory abnormality, or psychiatric illness that would interfere with or prevent the subject from participating in the study